By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Vaccinex, Inc. 

1895 Mt. Hope Avenue

Rochester  New York  14620  U.S.A.
Phone: 585-271-2700 Fax: 585-271-2766



Company News
Vaccinex, Inc. Announces Preliminary Data From The SIGNAL Clinical Trial (Investigational Drug VX15/2503 As A Potential Treatment For Huntington’s Disease) 4/24/2017 9:01:04 AM
biOasis Enters Into A License Agreement With Vaccinex, Inc. 9/23/2016 1:34:14 PM
Vaccinex, Inc. Receives Orphan Drug Designation From U.S. FDA For Its Lead Antibody Product Candidate, VX15, As A Potential Treatment For Huntington’s Disease 8/24/2016 7:29:22 AM
Vaccinex, Inc. Receives FDA Fast Track Designation For VX15 Antibody For The Treatment Of Huntington’s Disease 8/1/2016 8:23:34 AM
Vaccinex, Inc. Announces Publication Of Results From A Phase I Trial Of Anti-Semaphorin 4D Antibody, VX15/2503, In Patients With Advanced Solid Tumors 10/21/2015 7:28:26 AM
Vaccinex, Inc. Announces The Initiation Of A Phase 2 Clinical Trial Of Its Investigational VX15/2503 Antibody In Huntington's Disease (The SIGNAL Trial) 6/24/2015 11:45:43 AM
Vaccinex, Inc. Provides An Update On Its VX15/2503 Phase 1 Clinical Trial In Multiple Sclerosis Patients 3/31/2015 12:11:20 PM
Vaccinex, Inc. Signs Multi-Target Antibody Discovery Deal With Five Prime Therapeutics, Inc. (FPRX) 3/20/2015 7:11:10 AM
Vaccinex, Inc. Announces The Publication Of Data Demonstrating Preclinical Efficacy In An Animal Model Of Huntington Disease 2/18/2015 7:41:54 AM
Vaccinex, Inc. Announces Groundbreaking Preclinical Data Demonstrating An Immunomodulatory Role For Anti-SEMA4D Antibody Blockade In Colon And Breast Cancer 1/27/2015 9:55:14 AM